Head-to-Head drug battle offers new hope for stubborn Crohn's
NCT ID NCT07149467
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This study tests two medications, ustekinumab and upadacitinib, in people with Crohn's disease that hasn't responded to standard treatments. About 454 adults who have already failed or cannot tolerate anti-TNF therapy will receive one of the two drugs. The goal is to see which drug works better at putting the disease into remission by week 16, helping doctors and patients choose the best option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE AGGRAVATED are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.